Enanta Pharmaceuticals to Present at the 35th Annual J.P. Morgan Healthcare Conference

December 22, 2016

- **Presentation and Question and Answer Session to be Webcast beginning at 9:00 a.m. PT on January 11, 2017**

WATERTOWN, Mass.--(BUSINESS WIRE)--Dec. 22, 2016-- Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will make a formal presentation at the 35th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2017. The presentation will contain a business overview and an update on Enanta's research and development pipeline. A question and answer session with investors will follow the presentation.

A live webcast and replay of the presentation, as well as the question and answer breakout session that follows the presentation will be accessible by visiting the "Calendar of Events" section on the "Investors" page of Enanta's website at www.enanta.com. The replay webcasts will be available following the presentation and will be archived for approximately 60 days.

About Enanta
Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. Enanta's research and development efforts are currently focused on four disease targets: Hepatitis C Virus (HCV), Non-alcoholic Steatohepatitis (NASH), Respiratory Syncytial Virus (RSV) and Hepatitis B Virus (HBV).

Enanta has discovered novel protease inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). These protease inhibitors, developed through Enanta's collaboration with AbbVie, include paritaprevir, which is contained in AbbVie's marketed DAA regimens for HCV, and glecaprevir (ABT-493), Enanta's second protease inhibitor product, which AbbVie has developed in Phase 3 studies as part of an investigational, pan-genotypic, once-daily, ribavirin-free, fixed-dose combination (G/P) with pibrentasvir (ABT-530), AbbVie's second NS5A inhibitor. AbbVie has announced it has filed an NDA for G/P with the FDA and is on track to submit a marketing authorization application for G/P in the European Union in early 2017.

Enanta has also discovered EDP-305, an FXR agonist product candidate for NASH, currently in Phase 1 clinical development, as well as a cyclophilin inhibitor, EDP-494, a novel host-targeting mechanism for HCV, which is also in Phase 1 clinical development. In addition, Enanta has early lead candidates for HBV and RSV in preclinical development. Please visit www.enanta.com for more information on Enanta's programs and pipeline.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161222005683/en/

Source: Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc.
Carol Miceli, 617-607-0710
cmiceli@enanta.com